Health Care Select Sector SPDR® ETF (XLV)
83.88
+0.09 +0.11%
NYSE Arca
Oct 20, 20:00
Delayed 2m
USD
XLV Key Stats
| Expense Ratio | 0.14% |
| Share Class Assets Under Management | 17.89B |
| 30-Day Average Daily Volume | Upgrade |
| Net Asset Value | 83.88 |
| Discount or Premium to NAV | 0.01% |
| Turnover Ratio | 8.00 |
View All XLV News
XLV News
-
WireHeadlineTime (ET)
-
SA Breaking News10/20 16:53
-
MT Newswires10/20 13:16
-
MT Newswires10/20 09:21
-
Yahoo10/20 08:00
-
SA Breaking News10/19 15:49
-
MT Newswires10/19 13:15
-
Yahoo10/19 13:13
-
MT Newswires10/19 09:20
-
SA Breaking News10/18 15:51
-
MT Newswires10/18 13:05
XLV Performance
| Total Return (Price) | Total Return (NAV) | Cat. Total Return (NAV) | % Rank in Cat. (NAV) | |
|---|---|---|---|---|
| 1M | 2.29% | 2.27% | 1.36% | 23 |
| 3M | 3.84% | 3.90% | 2.54% | 21 |
| 6M | 14.04% | 14.10% | 13.08% | 33 |
| 1Y | 21.22% | 21.16% | 21.47% | 50 |
| 3Y | 12.32% | 12.32% | 10.28% | 33 |
| 5Y | 17.44% | 17.41% | 17.22% | 50 |
| 10Y | 11.02% | 11.02% | 11.91% | 60 |
XLV Asset Allocation
| Type | % Net | % Long | % Short |
|---|---|---|---|
| Cash | 0.00 | 0.00 | 0.00 |
| Stock | 99.87% | 99.87% | 0.00 |
| Bond | 0.00 | 0.00 | 0.00 |
| Convertible | 0.00 | 0.00 | 0.00 |
| Preferred | 0.00 | 0.00 | 0.00 |
| Other | 0.13% | 0.13% | 0.00 |
XLV Region Exposure
| Americas | 100.0% |
| North America | 100.0% |
| Latin America | 0.00 |
| Greater Europe | 0.00 |
| United Kingdom | 0.00 |
| Europe Developed | 0.00 |
| Europe Emerging | 0.00 |
| Africa/Middle East | 0.00 |
| Greater Asia | 0.00 |
| Japan | 0.00 |
| Australasia | 0.00 |
| Asia Developed | 0.00 |
| Asia Emerging | 0.00 |
| Market Classification | |
| % Developed Markets | 100.0% |
| % Emerging Markets | 0.00 |
XLV Stock Sector Exposure
| Basic Materials | 0.00 |
| Communication Services | 0.00 |
| Consumer Cyclical | 0.00 |
| Consumer Defensive | 0.00 |
| Energy | 0.00 |
| Financial Services | 0.00 |
| Healthcare | 99.29% |
| Industrials | 0.00 |
| Real Estate | 0.00 |
| Technology | 0.71% |
| Utilities | 0.00 |
XLV Stock Market Capitalization
| Giant | 57.28% |
| Large | 33.48% |
| Medium | 9.14% |
| Small | 0.10% |
| Micro | 0.00 |
XLV Stock Style Exposure
| Large Cap Value | 14.88% |
| Large Cap Blend | 38.91% |
| Large Cap Growth | 36.97% |
| Mid Cap Value | 1.55% |
| Mid Cap Blend | 3.23% |
| Mid Cap Growth | 4.36% |
| Small Cap Value | 0.00 |
| Small Cap Blend | 0.10% |
| Small Cap Growth | 0.00 |
View More Holdings
As of Oct. 20, 2017
XLV Top 10 Holdings
| Symbol | Name | % Weight | Price | % Chg |
|---|---|---|---|---|
| JNJ | Johnson & Johnson | 11.85% | 142.40 | +0.25% |
| PFE | Pfizer Inc | 6.74% | 36.42 | +0.50% |
| UNH | UnitedHealth Group Inc | 6.27% | 207.49 | +2.09% |
| MRK | Merck & Co Inc | 5.42% | 63.88 | +0.20% |
| ABBV | AbbVie Inc | 4.75% | 96.10 | -0.39% |
| AMGN | Amgen Inc | 4.14% | 182.96 | -0.63% |
| MDT | Medtronic PLC | 3.31% | 78.34 | -0.18% |
| BMY | Bristol-Myers Squibb Company | 3.29% | 64.42 | -0.39% |
| GILD | Gilead Sciences Inc | 3.29% | 81.21 | -0.47% |
| CELG | Celgene Corp | 2.94% | 121.33 | -10.76% |
Advertisement
XLV One Page Reports
- One Page Report Download
XLV Basic Info
| Style | |
|---|---|
| Equity Style | Large Cap/Growth |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Category Name | Health |
| Prospectus Objective | Specialty - Health |
| Fund Owner Firm Name | SPDR State Street Global Advisors |
| Benchmark Index | |
|---|---|
S&P Health Care Select Sector TR USD |
100.0% |
XLV Manager Info
| Name | Tenure |
|---|---|
| Dwayne Hancock | 0.74 yrs |
| Karl Schneider | 2.67 yrs |
| Michael Feehily | 6.67 yrs |
XLV Net Fund Flows
| 1M | 98.75M |
| 3M | -352.93M |
| 6M | 311.22M |
| YTD | 1.534B |
| 1Y | 3.202B |
| 3Y | 3.443B |
| 5Y | 5.957B |
| 10Y | 8.299B |
XLV Risk Info
| Beta (5Y) | 0.907 |
| Max Drawdown (All) | 40.58% |
| Historical Sharpe (10Y) | 0.7968 |
| Historical Sortino (All) | 0.7138 |
| 30-Day Rolling Volatility | 7.44% |
| Daily Value at Risk (VaR) 1% (All) | 3.03% |
| Monthly Value at Risk (VaR) 1% (All) | 13.22% |
XLV Fundamentals
| Dividend Yield TTM (10-20-17) | 1.42% |
| SEC Yield (10-20-17) | 1.41% |
| Weighted Average PE Ratio | 23.71 |
| Weighted Average Price to Sales Ratio | 1.914 |
| Weighted Average Price to Book Ratio | 3.931 |
| Weighted Median ROE | 22.78% |
| Weighted Median ROA | 8.15% |
| Forecasted Dividend Yield | 1.65% |
| Forecasted PE Ratio | 22.21 |
| Forecasted Price to Sales Ratio | 1.799 |
| Forecasted Price to Book Ratio | 3.530 |
| Number of Holdings | 63 |
XLV Growth Estimates
| Forecasted 5 Yr Earnings Growth | 9.05% |
| Forecasted Book Value Growth | 9.31% |
| Forecasted Cash Flow Growth | 14.64% |
| Forecasted Earnings Growth | 11.42% |
| Forecasted Revenue Growth | 9.94% |
XLV Comparables
EditXLV Attributes
| Key Dates | |
|---|---|
| Inception Date | 12/16/1998 |
| Last Annual Report Date | 9/30/2016 |
| Last Prospectus Date | 1/31/2017 |
| Attributes | |
| Exchange Traded Share | Yes |
| Exchange Traded Note | No |
| Enhanced Index Fund | No |
| Index Fund | Yes |
| Inverse Fund | No |
| Leveraged Fund | No |
| Fund of Funds | No |
| Currency Hedged Fund | No |
| Synthetic Replication Fund | No |
| Has Dividend Investment Plan | Yes |
| General Availability | |
| Available for Insurance Product | No |
| Available for Retirement Plan | No |
| Available for RRSP | No |
XLV Excel Add-In Codes
- Name: =YCI("XLV","name")
- Broad Asset Class: =YCI("XLV", "broad_asset_class")
- Broad Category: =YCI("XLV", "broad_category_group")
- Prospectus Objective: =YCI("XLV", "prospectus_objective")
To find the codes for any of our financial metrics, see our Complete Reference of Metric Codes.
Access our powerful Excel Add-in with a YCharts Professional Membership. Learn More.
Advertisement
